Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene Expression of A375 Cells After Fluvastatin Treatment

ABSTRACT: Gene Expression of A375 Cells After Fluvastatin Treatment

PROVIDER: PRJNA674663 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12983479.fastq.gz	Fastqsanger.gz
	SRR12983480.fastq.gz	Fastqsanger.gz
	SRR12983481.fastq.gz	Fastqsanger.gz
	SRR12983482.fastq.gz	Fastqsanger.gz
	SRR12983483.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Gene Expression of A375 Cells After Fluvastatin Treatment

Project description:Despite advances in melanoma treatment, more than 70% of patients with distant metastasis die within 5 years. Proactive treatment of early melanoma to prevent metastasis could save lives and reduce overall healthcare costs. Currently, there are no treatments specifically designed to prevent early melanoma from progressing to metastasis. We used the Connectivity Map (cMap) to conduct an in silico drug screen and identified HMGCR inhibitors (statins) as a drug class that might prevent melanoma metastasis. To confirm the in vitro effect of statins, RNA-sequencing was completed on A375 cells after treatment with fluvastatin to describe changes in the melanoma transcriptome. Statins induced differential expression in genes associated with metastasis and used in commercially available prognostic tests for melanoma metastasis.

2023-11-04 | GSE160870 | GEO

Effects of fluvastatin treatment on monocyte gene expression in SLE patients

Project description:The present gene expression array study of fluvastatin effects on monocytes from SLE patients show that fluvastatin has a global anti-inflammatory effect on monocytes, which includes attenuated expression of several proinflammatory cytokines, and regulated expression of molecules mediating lipoprotein signaling and cholesterol metabolism, as well as atherosclerosis and inflammatory signaling. Twenty seven SLE patients were given 20mg/day fluvastatin for one month. Blood samples were obtained before the starting of the treatment and at the end of treatment. Total RNA from monocytes was extracted using TRIzol reagent. RNA quality control was performed in a 2100 Bioanalyzer. Complementary RNAs from six SLE patients (four before treatment and two after treatment) were prepared for hybridization in an Agilent G4112F platform (Whole human Genome microarray 44K) using the One-color gene expression system (Agilent technologies).

2014-03-12 | E-GEOD-45422 | biostudies-arrayexpress

Effects of fluvastatin treatment on monocyte gene expression in SLE patients

2014-03-12 | GSE45422 | GEO

Effect of fluvastatin-treatment on the proteome and phosphor-proteome in metastatic pancreatic cancer cells

Project description:Fluvastatin has been identified as novel inhibitors of metastasis in pancreatic cancer. In multiple in vivo and in vitro experiments the compounds phenotypic effects was validated. Since under drug treatment the transcriptomic changes in examined cell lines were rather small, we expected the underlying mechanistic effect to be on the level of the proteome and more importantly the phospho-proteome. To evaluate this assumption we performed label-free full proteome and phosphoproteomics experiments on Fluvastatin treated ASPC1 cells.

2021-11-29 | PXD022345 | Pride

Expression data from ASPC1-GFP PDAC cells treated with fluvastatin

Project description:Drug treatments often result in dramatic changes in gene expression. Thus, we used microarray to uncover gene expression effects of fluvastatin treatment on ASPC1-GFP PDAC cells.

2021-11-23 | GSE161536 | GEO

Fluvastatin mitigates SARS-CoV-2 infection in human lung cells

Project description:Clinical data of patients suffering from COVID-19 have indicated that statin therapy, used to treat hypercholesterolemia, is associated with a better clinical outcome. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that fluvastatin inhibited coronavirus infection, while other tested statins did not. Fluvastatin inhibited high and low pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Proteomic analyses of infected versus uninfected lung epithelial cells treated with fluvastatin, simvastatin, or rosuvastatin revealed that all tested statins modulated the cholesterol synthesis pathways without compromising the innate antiviral immune response. Strikingly, fluvastatin treatment uniquely affected the proteome of SARS CoV 2 infected cells, specifically downregulating proteins that modulate protein translation and viral replication. These results suggest that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin may have a moderate beneficial effect on SARS CoV-2 infection by modulating protein translation.

2021-12-07 | PXD023422 | Pride

gene-expression profiling between UBE2S knock down A375 cells and control A375 cells

Project description:gene-expression profiling between UBE2S knock down A375 cells and control A375 cells

| PRJNA476507 | ENA

gene-expression profiling between UBE2S knock down A375 cells and control A375 cells

Project description:investigate the gene expression change between UBE2S konck down A375 cells mediated by Lentivirus and control A375 cells.

2018-06-19 | GSE115922 | GEO

Gene expression changes caused by treatment of A375 cells with A-366 versus DMSO (vehicle)

Project description:We use RNAseq to examine gene expression changes in A375 cells after treatment with A-366 versus DMSO (vehicle) of mScarlet tagged H3.3(wildtype) vs. H3.3(K9M)

2022-01-02 | GSE192612 | GEO

Fluvastatin-induced differential global gene expression in human malignant MCF-7 breast cancer cells

Project description:The current study analyzed the altered expression profiles of genes that are responsible for fluvastatin-induced breast cancer cell death in MCF-7 cells (ER+ve luminal breast cancer cells). Some of these altered gene expressions were further inter connceted to various pathways which may eventually be recognised as drug targets/ biomarkers in statin-sensitve breast cancer patients. To understand the differential gene expression profile in fluvastatin treated (24 h) malignant breast cancer cells with untreated malignant breast cancer cells.

2014-09-01 | E-GEOD-59006 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data